Relativity-104 is revealed as a failure, and the phase 3 it just spawned could fail too.

Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.

Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.

So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.

Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.

Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.

Patients' expression of CEACAM5 might hold the key to activity after all.

Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.